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Synopses

Rhodococcus equi and Arcanobacterium
haemolyticum: Two “Coryneform”
Bacteria Increasingly Recognized
as Agents of Human Infection
Regina Linder
Hunter College, New York, New York, USA

Rhodococcus equi and Arcanobacterium haemolyticum, formerly classified in the
genus Corynebacterium, are members of the loosely defined taxon “coryneform” bacteria. Although they are the etiologic agents of distinct human infections, both organisms
are frequently overlooked, which results in missed or delayed diagnoses. R. equi, long
known as an important pathogen of immature horses, has become in the past three
decades an opportunistic pathogen of severely immunosuppressed humans. Most
cases are secondary to HIV infection. When specifically sought in throat swab cultures,
A. haemolyticum is found responsible for 0.5% to 2.5% of bacterial pharyngitis,
especially among adolescents. These two microorganisms represent a spectrum of
disease in humans: from a mild, common illness to a rare life-threatening infection.
Each organism elaborates lipid hydrolyzing enzymes (cholesterol oxidase by R. equi
and sphingomyelinase D by A. haemolyticum) that are toxic to animals and humans
and damaging to mammalian cell membranes. The participation of the cytotoxins in
pathogenicity is discussed. Greater awareness of the properties of these two bacteria
may promote faster, more accurate diagnoses and better clinical management.

A variety of factors contribute to the underreporting of human infections caused by bacteria
in the genus Corynebacterium and closely related
genera. The group, often referred to as “coryneform,” comprises taxonomically diverse grampositive rods resembling Corynebacterium diphtheriae and displaying pleomorphism and irregular cellular arrangements (1,2). The group
includes human and animal pathogens, as well as
commensal bacteria. The control of diphtheria in
industrialized countries and the subsequent
deemphasis of the genus Corynebacterium have
contributed to discounting isolates characteristic
of the genus as contaminants. Even reference
laboratories report difficulty in the speciation of
gram-positive pleomorphic rods that resemble
corynebacteria (1). Because of the emergence of a
number of coryneform bacteria as important
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human pathogens, rigorous biochemical and
molecular tools have increasingly been applied to
isolates. The resulting improved epidemiology
and taxonomy have led, for example, to the definition of CDC groups JK and D-2 in the genus
Corynebacterium, now recognized as important
opportunistic pathogens (1). Similarly, more accurate characterization of some species caused
them to be removed from the genus Corynebacterium. Excellent reviews of the pathogenicity
and epidemiology of these diverse genera have
been published (1,2). This article explores two
pathogenic coryneform bacteria: Rhodococcus equi,
a rare often fatal human pathogen, in which
virtually all human infections occur among compromised hosts; and Arcanobacterium haemolyticum, which is responsible for many respiratory
infections in healthy people. This article aims to
bring about improved recognition of these two
easily overlooked pathogens and considers mechanisms underlying the diseases, the immune
response of the hosts, and treatment protocols.
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Epidemiology and Clinical Presentation

with antimicrobial agents than cases in AIDS
patients (8). Most often, patients have a slowly
progressive granulomatous pneumonia, with
lobar infiltrates, frequently developing to cavitating
lesions visible on chest x-ray. Other sites of
infection include abscesses of the central nervous
system, pelvis, and subcutaneous tissue, and
lymphadenitis (7,8-10). Cases of lung infection
caused by inhalation and cutaneous lesions caused
by wound contamination have been documented;
the latter are almost the only R. equi infections
reported in healthy persons, frequently children
(11). Delays in accurate diagnosis of R. equi are
still common (2,7), despite increased awareness
of this organism as an opportunistic pathogen in
humans. Factors for delayed diagnosis include
the insidious onset of disease, clinical resemblance
of the infection to mycobacterial, fungal, and
actinomycotic infections, and the relatively nondescript bacteriologic profile of R. equi. Morphology,
partial acid fastness, and a distinctive histopathologic profile in bronchial specimens (Figure 1
A and B) contribute to accurate diagnosis.
Numerous polymorphonuclear leukocytes with
intracellular pleomorphic gram-positive bacteria,
microabscesses, pseudotumors, and malakoplakia
are noted on tissue (7,11). Malakoplakia is a
relatively rare granulomatous inflammation not

R. equi
Originally isolated by Magnusson in 1923
from granulomatous lung infections in young
horses (3), Corynebacterium (now Rhodococcus
equi) remains an important pathogen of foals.
Much of the considerable body of knowledge about
R. equi, including its pathogenicity and immune
response to infection, derives from veterinary
studies and has been recently updated (4).
R. equi is readily found in soil, especially
where domesticated livestock graze (5). The stool
of horses and other animals is the source of soil
contamination. Infection in humans derives from
environmental exposure (2,5), and the organism
may be ubiquitous in soil (6). While early cases
occurred mostly in persons with a history of
contact with horses, only 20% to 30% of recent
cases can be traced to such contact (7). A review of
cases in the three decades since the first reported
human infection in 1967 is presented in Table 1.
R. equi is a rare opportunistic pathogen found
in severely compromised patients, and most commonly in recent years, in human immunodeficiency virus (HIV)-infected persons. Early cases,
most in patients receiving immunosuppressant
therapy, were more likely to be successfully treated

Table 1. Rhodococcus equi case reports in humans: 1967–1996

Years
1967–76

Cases
7

Predisposing condition
(number)
Corticosteroid (1)
Cancer/immunosuppressant (3)
Renal transplant (2)
Noneb (1)

Primary site
of infection
(number)
Lung (6)
Lymphatic (1)

1977–86

15

Corticosteroid (1)
Cancer/immunosuppressant (4)
Renal transplant (2)
HIV (7)
Alcoholism (1)

Lung (14)
Blood (1)

1987–96

93

Cancer/immunosuppressant (8)
Renal transplant (3)
HIV (67)
Otherc (8) (1b)
None (7) (4b)

Lung (72)
Lymphatic (2)
Blood (8)
Wound (6)
Otherd (5)

Deaths
0

Referencesa
8–10

8

8–10,22

34

8–13,22

a

In the interest of space, case compilations are cited in lieu of individual case reports.
Child
c
Includes intravenous drug use, lab infection, emphysema, kidney disease.
d
Central nervous system, gastrointestinal
b
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A

B

Figure 1. A. Bronchial tissue Gram stain showing
intrahistiocytic coccobacillary forms of Rhodococcus
equi. Original magnification, x 1,000. B. Open lung
biopsy showing coalescent microabscesses with
numerous histiocytes containing Rhodococcus equi
organisms. PAS stain. Original magnification x 250.
Figure provided by Dr. Margie Scott, Vanderbilt
University Medical Center.

typically associated with histology of lung infection and can be of help in forming a differential
diagnosis (11,12). Firm diagnosis and differentiation from similar pathogens require the isolation and identification of R. equi from sputum,
bronchial washings, open-lung biopsy, or other
specimens reflective of pathology. Blood cultures
from severely immunosuppressed patients with
focal R. equi infection often contain the organism.
In sixty-five percent of cases secondary to HIV
infection, the organism is found in patients’ blood
cultures (11). Deaths exceed 50% among AIDS
patients with documented R. equi pneumonia and
are almost always preceded by multiple relapses,
which are common even when successful
treatment is ultimately achieved (Table 1; 13).

Vol. 3, No. 2, April–June 1997

Corynebacterium haemolyticum
A. haemolyticum was first described and
named by MacClean et al. (14), who isolated it
from pharyngeal infections in U.S. soldiers and
natives in the South Pacific. Classification of the
organism generated controversy until the definition in 1982 of a new genus, Arcanobacterium
(secretive bacterium), in which it remains the
only species (15).
Unlike R. equi infection, where invasive clinical disease underscores the need to detect and
identify the causative agent of infection, A. haemolyticum infection is often reported from deliberate
screening for the organism of a large number of
patients with sore throats. After it was identified
during World War II from patients with pharyngitis (14), it was occasionally reported from Europe,
the United States, and in 1981, Sri Lanka (16
cases) (16). Most cases involve pharyngitis and/or
tonsillitis, and approximately 50% are exudative.
Throat infections are often accompanied by cervical lymphadenopathy (17,18). Diagnosis of cases
(distinct from screening studies) often occurs only
after recurrent infections, which are thought to be
related to incorrect initial diagnosis, resulting in
less-than-optimum treatment (19). Infection is
most common in 15- to 25-year-old persons, and is
thought to result from droplet transfer from
infected persons (20). Symptoms resemble those
of ß-hemolytic streptococci or viral infection. The
spectrum of disease ranges from sore throat to, in
rare cases, a life-threatening membranous pharyngitis resembling diphtheria (18,20). An erythematous morbilliform or scarlatinal rash of the
trunk, neck, or extremities is associated with 20%
to 25% of cases (19), enhancing the possibility of
misdiagnosis as streptococcal infection or penicillin
allergy, because ß-lactam therapy is frequently
initiated without accurate diagnosis. A recent
report des-cribes in detail the dermatologic
manifestations of A. haemolyticum infection (20).
The demonstration that A. haemolyticum is
not a component of the human commensal flora
was essential to establishing its role in human
infection. Studies of more than 2,000 cases each
found the organism only in association with
clinical symptoms (17,19). Table 2 summarizes
several case compilations, including the incidence
of infection among culture-positive bacterial sore
throats, as well as data on coinfection. Some 0.5%
to 3% of cases of pharyngitis can be traced to
A. haemolyticum depending on the population
studied, with the highest numbers among 15- to
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Table 2. Representative pharyngitis screenings for Arcanobacterium haemolyticum
Period of study Number of
Incidencea
(reference)
isolations
Rash
Coinfection
(%)
1978–80(16)
16
0
13 (C. diphtheriae,
NR
S . pyogenes, E. coli,
P. aeruginosa)
37
NR
2.0
1981–85 (19)
81b
1990–92(17)

42

17

NR

0.36

1991–92(42)

19

5

0.49

1992–95(43)

16

12

11 (streptococci,
groups A, B, G)
5 (streptococci,
groups A, B,
ß-hemolytic)

0.75

Clinical features
(population)
Symptomatic throat
swabs and pyoderma (Sri
Lanka)
Symptomatic throat
swabs (Sweden)
Symptomatic throat
swabs; 5 cases monospot
positive (Ottawa, Canada)
Symptomatic throat swabs,
3922c; (Finland)
Symptomatic throat swabs,
2121c; (Czech Republic)

NR-not reported
a
Incidence refers to the proportion of sore throat cases in each study cited yielding A. haemolyticum.
b
1 of 550 asymptomatic specimens yielded A. haemolyticum.
c
Figures refer to the total specimens screened.

30-year-old patients (19). Clearly, accurate diagnosis depends on differentiating A. haemolyticum
from more common pathogens. A. haemolyticum
occurs relatively often in polymicrobic infections together with typical respiratory pathogens such as streptococci. The isolation of
classical pathogens from specimens that also
contain A. haemolyticum exacerbates the tendency to overlook the organism.

Taxonomy, Bacteriology, and
Differential Identification
R. equi
On the basis of the chain length of mycolic
acids and other properties of its lipids, R. equi
was reclassified in the suprageneric taxon
nocardioform actinomycetes (1,2,5). R. equi is a
strictly aerobic gram-positive bacterium
displaying rod-to-coccus pleomorphism, with
fragmenting and occasionally palisading forms.
It is nonfastidious. Colonies on blood agar from
clinical specimens can be mucoid and coalescing.
Typical salmon pink pigmentation develops on
blood agar, but often only after 2 to 3 days
incubation. Growth on Lowenstein-Jensen
medium allows earlier detection of pigment (M.
Scott, pers. comm.). Positive routine biochemical
tests include catalase and urease, but R. equi is
generally nonreactive. Acid-fast staining of
direct smears and fresh isolates is helpful in
identification but is rarely observed on subculture
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(5,7). Some diagnostic laboratories use a
commercial kit (API Coryne strip (bioMerieuxVitek, Hazelwood, MO) for identification.
Also helpful in identifying R. equi is synergistic hemolysis (resembling the CAMP test), displayed by cross-streaking on sheep blood agar
with any of a number of other bacteria, including
A. haemolyticum, Staphylococcus aureus, and
Corynebacterium pseudotuberculosis (21; Figure
2). Synergistic hemolysis is discussed among
mechanisms of pathogenesis (below). In addition,
antagonism between imipenem and other ß-lactam
antibiotics used against strains of R. equi provides the opportunity of differentiating the
organism from taxonomically related species (22).
A. haemolyticum
Organisms are gram-positive rods—slender
at first, sometimes clubbed, or in angular
arrangements. Coccal forms predominate as the
organism grows. The organism is facultatively
anerobic. Growth is enhanced in blood and in the
presence of CO2. Some sugars are fermented, and
the organism is catalase negative. Hemolysis is
best observed on human blood, and Gaston et al.
(20) suggest routine plating of specimens
suspected of containing A. haemolyticum on
human blood agar to distinguish Streptococcus
pyogenes. Pitting beneath colonies on human
blood agar is helpful in identification. Synergistic
hemolysis with R. equi (or inhibition of the
hemolytic zone of S. aureus, (Figure 2) is useful in
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Figure 2. Cooperative (and antagonistic) hemolytic
reactions on sheep blood agar, demonstrating cooperative
hemolysis between Rhodococcus equi, Arcanobacterium
haemolyticum, and Staphylococcus aureus. Partial
hemolysis by S. aureus (cross-hatched on diagram) is
inhibited in the proximity of A. haemolyticum.

identification, especially as it may rule out group
B streptococci. Poor growth on tellurite assists in
differentiation from Corynebacterium diphtheriae.

Pathogenesis and the Immune Response
R. equi
Because R. equi is a rare and recently
emergent cause of human infection, mechanisms
of its pathogenicity are not well defined.
However, the much-studied infection in foals and
an experimental model in mice provide data
which, together with the available human data,
give insight into the workings of the pathogen. Its
nature as a facultatively intracellular bacterium,
able to persist, grow, and ultimately destroy
macrophages (23-25), is the property of R. equi
most closely associated with virulence in each
host. Foal alveolar macrophages having ingested
R. equi did not undergo phagosome-lysosome
fusion and were irreversibly damaged in electron
micrographs (26). Results of pathology tests
(microscopy and roentgenography) reflect significant inflammation, consistent with that found
in such other intracellular pathogens as Mycobacterium tuberculosis, which elude pulmonary
clearance. Open lung biopsies in humans show
numerous polymorphonuclear leukocytes, foam
cells, and cavitating lesions with intracellular
bacteria (7,11; Figure 1). Also as in mycobacteria,
cell wall mycolic acids are present. These acids
may contribute to the ability of R. equi to grow in
macrophages; virulence of strains for mice was
found related to the carbon chain length of the
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molecules (27). Granuloma formation was
observed when killed R. equi strains, regardless
of virulence, were introduced into inbred mice,
supporting a role for mycolic acids or other cell
wall glycolipids in pulmonary inflammation (28).
A key contributor to virulence in the foal and
the mouse model is a group of large (85-90 kb)
plasmids, encoding 15-17 kDa antigens among
strains isolated from almost all natural infections in foals (29). Strains cured of the plasmid
are cleared in experimental infections, and intracellular replication in murine macrophages is
greatly diminished in its absence (25,28). In
contrast, of 39 strains isolated from humans (29
with AIDS), 31 strains did not express the
virulence associated plasmid and were nonvirulent in mice (6). The investigators suggest
that intracellular growth and, therefore, virulence
among human strains may not be explained by
the same determinants as foals, while mycolic
acids may play a role.
Nordmann (23) found that intracellular
growth in mouse and human macrophages of
strains isolated from AIDS patients was related
to ß-lactam resistance, the production of a bacteriophage, and virulence in inbred mice. Virulence was not attributable to 17kDa virulence
antigens, but soluble cytotoxic substances were
associated with the virulent phenotype. The
cytotoxic activity remains to be characterized,
and its relationship to known cytotoxic activities
of R. equi remains to be elucidated. In addition to
numerous hydrolytic enzymes typical of the genus
Rhodococcus (5), strains of R. equi, irrespective of
virulence, produce cholesterol oxidase, which is
responsible for the organism’s participation in
synergistic hemolytic reactions with other bacteria (30; Figure 2). Experiments using cultured
mouse macrophages with phagocytosed R. equi
suggest a role for cholesterol oxidase in macrophage destruction in infections. Macrophages
undergo oxidation of membrane cholesterol, and
the accumulation of oxidized cholesterol is
significantly enhanced by the cophagocytosis of
C. pseudotuberculosis, a related coryneform
bacterium producing sphinomyelinase D (31).
Toxicity to vertebrates as a result of enzymatic
oxidation of membrane cholesterol is documented
in diverse systems, most dramatically by lethality to hypercholesterolemic rabbits (31).
Because R. equi is uniquely an opportunistic
pathogen in humans, it is of interest to consider
the precise nature of the immune deficiency that
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underlies susceptibility to this organism. Recent
investigations in immunodeficient mice are
especially instructive. T-cell subsets, specifically
functional CD4+ lymphocytes, are necessary to
effect complete clearance of R. equi challenge
(23,32). Specifically, Kanaly et al. showed that
CD4+ Th1 cells (expressing interferon-gamma)
are sufficient to achieve clearance from the lungs
of mice (32,33). Consistent with these data, peripheral mononuclear cells, from patients with
AIDS, challenged in vitro with R. equi failed to
secrete high levels of interferon-gamma in comparison with cells from healthy donors (34). Investigations implicating a specific defect in the Th1
phenotype in the pathogenicity of AIDS make these
studies especially provocative and suggest a role
for immunotherapy in R. equi infection (33).
While cell-mediated immunity appears to
have a primary role in protecting against R. equi
infection, the participation of humoral antibody
has been established in foals. Passive immunization with hyperimmune serum is efficacious
in prophylaxis, and severity of disease is
inversely related to circulating antibody (1,5).
Mastroianni et al. (35) demonstrated antibody to
the major antigens of R. equi in four AIDS
patients with cavitating pneumonia. The role of
such antibody in the natural history of the
infection remains to be elucidated.
A. haemolyticum
Little is known about the mechanisms by
which A. haemolyticum produces infection or
brings about the skin manifestations frequently
associated with it. The organism is known to
produce uncharacterized hemolytic agent(s) (20)
and two biochemically defined extracellular
products: a neuraminidase and a phospholipase
D (PLD) acting preferentially on sphingomyelin
and generating ceramide phosphate in the target
membrane (36). Of these, PLD is known to bring
about tissue damage, as elaborated by this organism as well as the closely related bacterium, C.
pseudotuberculosis, an important pathogen of
sheep. Soucek et al. (36) found that the enzyme
was responsible for the dermonecrotic, as well as
the synergistic hemolytic, activity of the organisms
that elaborate it. The PLD gene from A. haemolyticum has been cloned and shown to have a high
degree of homology with that of C. pseudotuberculosis, where it is thought to participate in
vascular permeability and dissemination of the
pathogen (37). Evidence relates PLD with toxicity
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of C. pseudotuberculosis. Targeted mutagenesis
of the PLD gene of C. pseudotuberculosis
confirmed the role of the enzyme in virulence and
specifically in dissemination in the host (38).
Mutant bacteria had a reduced ability to
establish infection in goats and were unable to
disseminate by the lymphatics to secondary sites.
A PLD sharing many properties with corynebacterial PLDs, including biochemical and
biological activities, is responsible for the toxicity
of the venom of the brown recluse spider (39). The
role of potentiated cytotoxicity caused by the
combined activity of PLD and cooperative agents
such as cholesterol oxidase in disease is not
established, but suggested by in vitro data
involving cophagocytosis as described above (31).

Treatment
R. equi
Increased recognition of R. equi as a cause of
life-threatening infection in severely immunocompromised persons has promoted a number of
studies of in vitro antimicrobial susceptibility of
clinical isolates (11,13,40,41). While variations
exist, most strains were susceptible to inhibition
by glycopeptide antibiotics (including vancomycin
and teicoplanin) and rifampin. Macrolide antibiotics, such as erythromycin and clarithromycin, were also inhibitory to many strains.
Resistance to ß-lactam antibiotics (with the
exception of carbapenems, specifically imipenem)
was generally reported, and is not related to the
production of a ß-lactamase.
Because of relapse in spite of treatment in a
majority of cases (11) and high mortality rate,
especially among AIDS patients (Table 1), there
is no standard treatment protocol for pulmonary
and/or systemic R. equi infections. However,
several principles reflect the accumulated experience of investigators. Careful and repeated
culture and susceptibility testing during treatment is required to discover acquired resistance,
in a manner similar to the treatment of
mycobacterial infection (11,22). Tolerance to the
cidal effects of some drugs and the need for longterm therapy (generally 2 months to life-long
treatment; 40,41) make bactericidal testing a
useful addition to laboratory studies. In consideration of the severe immunosuppression of
patients and proclivity to relapse, investigators
generally promote a combination of at least two
drugs parenterally (usually including a
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glycopeptide or rifampin) followed by oral
maintenance therapy (11,41). Recommendation of
lipophilic antimicrobials that penetrate macrophages is controversial (11,41). A proposed regimen
involves parenteral glycopeptide plus imipenem
for at least 3 weeks, followed by an oral combination of rifampin, plus either macrolides or
tetracycline (41). Examples of efficacious protocols
for parenteral treatment are available (Table 1).
Surgical lung resection has been reported
occasionally since the emergence of human cases,
especially where large focal lesions develop
(9,10), and has sometimes been efficacious in
combination with antimicrobial therapy. As
cases of R. equi continue to be recognized among
AIDS patients, antimicrobial prophylaxis against
this opportunistic pathogen may prove a benefit.
A. haemolyticum
In vitro testing of A. haemolyticum isolated
from human infections shows susceptibility to
erythromycin, gentamicin, clindamycin, and
cephalosporins (42). Reports of treatment failure
with penicillin in spite of low minimum
inhibitory concentrations have been attributed to
tolerance and to failure to penetrate the intracellular location of the pathogen. Erythromycin
has been proposed as the drug of choice, with
parenteral antimicrobial drugs used for serious
infections (20). The general similarity of the
susceptibility pattern of A. haemolyticum to more
commonly encountered pharyngeal pathogens,
including S. pyogenes, makes culture and accurate diagnosis essential if cases are to be
recognized for their true etiology. Its participation
in polymicrobic infections (Table 2) requires that
A. haemolyticum be specifically sought in appropriate specimens to obtain accurate diagnosis
and to allow epidemiologic analysis.

R. equi and A. haemolyticum represent
distinct poles of infectious disease: one a ubiquitous soil organism producing life-threatening
opportunistic infections and the other a readily
treatable respiratory infection of healthy young
persons. In both instances, a high degree of
suspicion is required to make accurate and timely
diagnoses of infections. Diagnostic failure may
result in a graver clinical profile including deaths
for R. equi and, in many undiagnosed or
misdiagnosed cases, for A. haemolyticum. As
members of the morphologically defined taxon
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“coryneform” bacteria, these organisms exemplify
properties of the group that require further
elucidation. Weakly pathogenic and noninvasive,
the group includes environmental bacteria; animal
pathogens “crossing-over” to become human opportunistic pathogens; commensals similarly infecting compromised hosts; and producers of a wide
variety of hydrolytic enzymes bearing a poorly
defined relation to virulence (1). Both R. equi and
A. haemolyticum elaborate a cytotoxic protein
(cholesterol oxidase or sphingomyelinase D) known
to be responsible for systemic harm to animals.
Coincidentally, these products potentiate each
other’s cytotoxic action. The participation of the
agents in harm to a host, alone or in combination
with other substances, is consistent with available data, but yet unproven. Of particular interest
is the role of cholesterol oxidase in destruction of
alveolar macrophages in R. equi pneumonia.
Clarifying the role of synergistic or cooperative
cytotoxins in one or more infectious diseases will
surely improve our understanding of others
because of the common occurrence of these
agents among bacterial pathogens (21). It is
difficult to envision the potentiated hemolytic
combination of R. equi and A. haemolyticum at
the site of an infectious lesion. However, cooperatively hemolytic combinations have been shown
to result from the partnership of hydrolytic
enzymes (e.g., phospholipases, which are ubiquitous in tissue) with the cytotoxins of pathogenic
bacteria (10). Similarly, the hydrolytic enzymes
of commensal bacteria or copathogens that occur,
for example, in A. haemolyticum pharyngitis,
can readily be envisioned to participate in
potentiated cytotoxicity in host tissue. Together
with improved recognition of these two pathogens,
greater understanding of their toxic products
should prove beneficial.
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